Welcome to our dedicated page for Achilles Therapeutics plc American Depositary Shares news (Ticker: ACHL), a resource for investors and traders seeking the latest updates and insights on Achilles Therapeutics plc American Depositary Shares stock.
Achilles Therapeutics plc (NASDAQ: ACHL) is a clinical-stage biopharmaceutical company dedicated to developing next-generation, AI-powered precision T-cell therapies for the treatment of solid tumors. The company's innovative approach harnesses the immune system to target and destroy cancer cells by focusing on clonal neoantigens—unique protein markers present on all cancer cells but absent from healthy tissue.
Achilles Therapeutics employs advanced DNA sequencing and its proprietary PELEUS™ bioinformatics platform to identify these clonal neoantigens. This precision allows for the development of tailored T-cell-based product candidates aimed at these specific cancer markers. The company has two ongoing Phase I/IIa clinical trials: CHIRON for advanced non-small cell lung cancer (NSCLC) and THETIS for recurrent or metastatic melanoma.
Recent achievements include the progress in clinical trials, with additional clinical and translational science data expected in the fourth quarter of 2023. The strong cash position of $158.5 million supports operations into mid-2025. The company continues to refine its manufacturing processes, notably the VELOS™ platform, which has significantly improved T-cell doses.
A notable collaboration with Arcturus Therapeutics aims to combine Achilles' AI-driven technology with Arcturus' self-amplifying mRNA platform to develop personalized cancer vaccines. This research highlights Achilles' commitment to leveraging cutting-edge technologies for cancer treatment.
Achilles has also received significant patents and regulatory recognitions, including a US patent for its neoantigen immunogenicity prediction and an Innovation Passport from the UK MHRA, underlining its leadership in the bioinformatics and immunotherapy sectors.
Looking ahead, Achilles plans to report more clinical data in the first quarter of 2024 and continue its focus on optimizing its T-cell therapies and expanding its technological capabilities.
Achilles Therapeutics has received approval to transfer its listing from the Nasdaq Global Market to the Nasdaq Capital Market, effective November 19, 2024. This transfer follows a May 17, 2024 notification from Nasdaq regarding non-compliance with the minimum bid price requirement of $1.00 per ADS. The company's ADSs will continue trading under the symbol ACHL. The transfer provides an additional 180 calendar days to regain compliance with the minimum bid price requirement. The company must demonstrate a closing bid price of at least $1.00 per share for ten consecutive business days to regain compliance.
Achilles Therapeutics (NASDAQ: ACHL) reported Q3 2024 financial results with a net loss of $19.6 million ($0.48 per share), compared to $16.7 million in Q3 2023. The company's cash position stood at $86.1 million as of September 30, 2024, with an additional $12.8 million R&D tax credit received in October. Following the discontinuation of its TIL-based cNeT program and closure of Phase I/IIa trials, Achilles has engaged BofA Securities to explore strategic options. R&D expenses increased to $16.4 million from $14.7 million year-over-year, while G&A expenses decreased to $4.0 million from $4.4 million.
Achilles Therapeutics (NASDAQ: ACHL) has announced a strategic update, discontinuing its TIL-based cNeT therapy program and closing the Phase I/IIa CHIRON and THETIS clinical trials. The company will refocus on exploring partnerships with third parties developing alternative modalities targeting clonal neoantigens for cancer treatment. Achilles has engaged BofA Securities to advise on value-maximizing strategies.
Key points:
- Cash position of $95.1 million as of June 30, 2024
- Implementing workforce reduction and cost-cutting measures
- Full clinical data from CHIRON and THETIS trials to be presented in an upcoming forum
- Exploring strategic alternatives, including potential acquisition, merger, or asset sale
Achilles Therapeutics (NASDAQ: ACHL) reported its Q2 2024 financial results and business updates. Key highlights include:
1. Research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered technology.
2. Interim Phase I/IIa update on cNeT in Advanced NSCLC and Melanoma, with improved cNeT persistence and engraftment in patients with enhanced host conditioning (EHC).
3. Cash position of $95.1 million, supporting operations through 2025.
4. Q2 2024 financials: R&D expenses $13.6 million, G&A expenses $4.2 million, net loss $16.4 million ($0.41 per share).
5. Appointment of Matilde Saggese, MD, as Interim Chief Medical Officer.
Achilles Therapeutics (NASDAQ: ACHL) has announced a research collaboration with Arcturus Therapeutics (NASDAQ: ARCT) to develop second-generation personalized mRNA cancer vaccines. This partnership aims to combine Achilles' AI-driven, tumor-targeting PELEUS technology with Arcturus' self-amplifying mRNA (sa-mRNA) STARR platform. The collaboration seeks to generate potent and durable T cell responses in pre-clinical studies. The IND-enabling research focuses on targeting clonal neoantigens, potentially benefiting patients in earlier stages of cancer. Achilles' ongoing CHIRON and THETIS Phase 2 trials will continue parallel to this new research endeavor.
Achilles Therapeutics (NASDAQ: ACHL) received a Nasdaq deficiency notice on May 16, 2024, regarding non-compliance with the $1.00 minimum bid price requirement for its American Depositary Shares (ADS). The company has until November 12, 2024, to regain compliance. If it fails, it may receive an additional 180-day period to meet the requirement. The notice does not immediately affect the listing of its ADSs, which will continue trading on the Nasdaq Global Select Market under the symbol 'ACHL'. Achilles plans to monitor and consider options to address the bid price issue.
Achilles Therapeutics reported its first-quarter 2024 financial results and recent business highlights, showcasing strong cash reserves of $112.3 million supporting operations through 2025. The company provided an interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma, with promising results from ongoing clinical trials. Despite a decrease in research and development expenses, the net loss for the first quarter ended March 31, 2024, was $12.3 million.
FAQ
What is the current stock price of Achilles Therapeutics plc American Depositary Shares (ACHL)?
What is the market cap of Achilles Therapeutics plc American Depositary Shares (ACHL)?
What is Achilles Therapeutics plc?
What are clonal neoantigens?
What clinical trials does Achilles Therapeutics currently have ongoing?
What is the PELEUS™ platform?
What recent achievements has Achilles Therapeutics made?
What is the collaboration with Arcturus Therapeutics about?
What is the financial position of Achilles Therapeutics?
What are the future plans for Achilles Therapeutics?
What regulatory recognitions has Achilles Therapeutics received?
How does Achilles Therapeutics leverage AI in its treatments?
